FDA Wants Your Gross Wound Stories to Guide New Drugs
Published Date: 5/29/2026
Notice
Summary
The FDA is hosting a public meeting on August 25, 2026, to hear from people living with nonhealing chronic wounds about how these wounds affect their daily lives and what they want from treatments. This meeting aims to shape better drug development by focusing on patient experiences and preferences. Anyone can join in person or online and share their thoughts by October 26, 2026, helping guide future treatments and clinical trials.
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10675 — Medical Devices; Neurological Devices; Classification of the Transcutaneous Electrical Nerve Stimulator To Treat Fibromyalgia Symptoms
The FDA is officially classifying the transcutaneous electrical nerve stimulator for fibromyalgia as a Class II device, meaning it’s safe and effective with some special rules. This change helps patients get easier access to this innovative treatment by cutting down red tape. The new classification is effective May 29, 2026, and could speed up device availability without extra costs for makers or users.
2026-10734 — Content of Human Factors Information in Medical Device Marketing Submissions; Guidance for Industry and Food and Drug Administration Staff; Availability
The FDA just released new guidance to help medical device makers include the right human factors info in their marketing submissions. This makes the review process faster and clearer for everyone involved. If you make or review medical devices, get ready to follow these updated steps starting now—saving time and possibly money!
2026-10703 — Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an Abbreviated New Drug Application; Guidance for Industry; Availability
The FDA just released final guidance to help drug companies prove their generic drugs work just like the original ones by using bioequivalence studies. This affects anyone submitting or updating abbreviated new drug applications (ANDAs) and aims to make the approval process clearer and smoother. Companies should review these new rules now to avoid delays and extra costs when getting their generics to market.
2026-10674 — Advisory Committee; Psychopharmacologic Drugs Advisory Committee; Renewal
The FDA is renewing the Psychopharmacologic Drugs Advisory Committee for two more years, keeping it active until June 4, 2028. This committee helps make sure psychiatric drugs are safe and effective, affecting drug makers, doctors, and patients. No new costs or big changes, just a smooth continuation of expert advice to keep mental health treatments on track.
2026-10615 — Food Additive Petition From Environmental Defense Fund, et al.; Request To Amend the Food Additive Regulations To Remove the Solvents Benzene, Ethylene Dichloride, Methylene Chloride, and Trichloroethylene; Reopening of the Comment Period
The FDA is reopening the comment period on a petition from the Environmental Defense Fund and others to remove four harmful solvents—benzene, ethylene dichloride, methylene chloride, and trichloroethylene—from food additive rules. This change affects food makers who use these solvents and aims to make our food safer. Comments are open until June 29, 2026, giving everyone a chance to share new info before any costly changes happen.
2026-10614 — Color Additive Petition from Environmental Defense Fund, et al.; Request To Amend the Color Additive Regulations To Remove the Solvents Ethylene Dichloride, Methylene Chloride, and Trichloroethylene; Reopening of the Comment Period
The FDA is reopening the comment period on a petition from the Environmental Defense Fund and others to remove three harmful solvents—ethylene dichloride, methylene chloride, and trichloroethylene—from color additive rules. This change affects companies using these solvents in color additives and aims to make products safer. Comments are open until June 29, 2026, giving everyone a chance to share new info before any final decisions.
Previous / Next Documents
Previous: 2026-10751 — Union Pacific Corporation and Union Pacific Railroad Company-Control-Norfolk; Southern Corporation and Norfolk Southern Railway Company
Union Pacific wants to take control of Norfolk Southern and combine their rail operations, creating one big railroad team. The Surface Transportation Board is reviewing this plan but has paused the process to ask for more info by July 27, 2026. This move could shake up the rail industry and affect how goods move across the country.
Next: 2026-10753 — Privacy Act of 1974; System of Records
HUD is updating its system that tracks debts and payments to keep your info safer and clearer. If you’re involved with HUD finances, these changes affect how your data is handled and protected. You’ve got until June 29, 2026, to share your thoughts before the new rules kick in, with no extra costs involved.